In pancreatic cancer models, GRP78-mediated chemotherapy resistance arises from its interaction with the extracellular domain of CLPTM1L/CRR9 on tumor cell surfaces. This evidence concerns the gene CLPTM1L and familial pancreatic carcinoma.